DEANNE OMAR: Open Payments
NPI 1730630674 · HENDERSON, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$980 in 41 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $90 · 2025 $980
Food & beverage: $896Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $292 |
| Janssen Biotech, Inc. | 11 | $219 |
| PFIZER INC. | 9 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| GENZYME CORPORATION | 3 | $64 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $56 |
| Novo Nordisk Inc | 2 | $36 |
| Madrigal Pharmaceuticals | 1 | $33 |
| Gilead Sciences, Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
Products named: RINVOQ, TREMFYA, VELSIPITY, DUPIXENT, ENTYVIO, SKYRIZI, XIFAXAN, Wegovy.
Industry payments across NV — which companies pay providers there.
